S1PR1 and COVID-19: Hence, S1P1 agonists and S1P2 antagonists could provide a new strategy for managing COVID‐19 by regulating the exaggerated inflammatory response against SARS‐CoV‐2 infection and the related endothelial dysfunction and stimulated inflammatory signaling pathways [19].